196 related articles for article (PubMed ID: 33323991)
21. Exposure-response analysis of the efficacy and safety of esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with or without diabetic kidney disease.
Yoshihara K; Fukae M; Kastrissios H; Wada R; Shimizu T
Drug Metab Pharmacokinet; 2024 Apr; 55():100535. PubMed ID: 38245949
[TBL] [Abstract][Full Text] [Related]
22. Effects of esaxerenone on blood pressure, urinary albumin excretion, serum levels of NT-proBNP, and quality of life in patients with primary aldosteronism.
Yoshida Y; Fujiwara M; Kinoshita M; Sada K; Miyamoto S; Ozeki Y; Iwamoto M; Mori Y; Nagai S; Matsuda N; Noguchi T; Okamoto M; Gotoh K; Masaki T; Shibata H
Hypertens Res; 2024 Jan; 47(1):157-167. PubMed ID: 37717115
[TBL] [Abstract][Full Text] [Related]
23. Effect of the Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, on Nocturnal Hypertension: A Post Hoc Analysis of the ESAX-HTN Study.
Kario K; Ito S; Itoh H; Rakugi H; Okuda Y; Yoshimura M; Yamakawa S
Am J Hypertens; 2021 May; 34(5):540-551. PubMed ID: 33165570
[TBL] [Abstract][Full Text] [Related]
24. Clinical Pharmacokinetics and Pharmacodynamics of Esaxerenone, a Novel Mineralocorticoid Receptor Antagonist: A Review.
Janković SM; Janković SV
Eur J Drug Metab Pharmacokinet; 2022 May; 47(3):291-308. PubMed ID: 35190999
[TBL] [Abstract][Full Text] [Related]
25. Effects of Repeated Oral Administration of Esaxerenone on the Pharmacokinetics of Midazolam in Healthy Japanese Males.
Toyama K; Furuie H; Kuroda K; Ishizuka T; Okuda Y; Shimizu T; Kato M; Igawa Y; Nishikawa Y; Ishizuka H
Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):685-694. PubMed ID: 34383278
[TBL] [Abstract][Full Text] [Related]
26. Nighttime home blood pressure lowering effect of esaxerenone in patients with uncontrolled nocturnal hypertension: the EARLY-NH study.
Kario K; Nishizawa M; Kato M; Ishii H; Uchiyama K; Nagai M; Takahashi N; Asakura T; Shiraiwa T; Yoshida T; Kaneshiro M; Taguchi T; Shiosakai K; Sugimoto K
Hypertens Res; 2023 Jul; 46(7):1782-1794. PubMed ID: 37173430
[TBL] [Abstract][Full Text] [Related]
27. Factors Associated with the Antihypertensive Effect of Esaxerenone and Serum Potassium Elevation: A Pooled Analysis of Seven Phase III Studies.
Ito S; Okuda Y; Sugimoto K
Adv Ther; 2023 Mar; 40(3):1242-1266. PubMed ID: 36662393
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment.
Kurata A; Yoshida T; Inoue M; Ishizuka T; Nakatsu T; Shimizu T; Kato M; Nishikawa Y; Ishizuka H
Adv Ther; 2020 Jan; 37(1):253-264. PubMed ID: 31705436
[TBL] [Abstract][Full Text] [Related]
29. Cardioprotective Effects of a Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, in Dahl Salt-Sensitive Hypertensive Rats.
Rahman A; Sawano T; Sen A; Hossain A; Jahan N; Kobara H; Masaki T; Kosaka S; Kitada K; Nakano D; Imamura T; Ohsaki H; Nishiyama A
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669786
[TBL] [Abstract][Full Text] [Related]
30. The renoprotective effect of esaxerenone independent of blood pressure lowering: a post hoc mediation analysis of the ESAX-DN trial.
Okuda Y; Ito S; Kashihara N; Shikata K; Nangaku M; Wada T; Sawanobori T; Taguri M
Hypertens Res; 2023 Feb; 46(2):437-444. PubMed ID: 36100672
[TBL] [Abstract][Full Text] [Related]
31. Absolute Bioavailability of Esaxerenone and Food Effects on its Pharmacokinetics After a Single Oral Dose in Healthy Japanese Subjects: An Open-Label Crossover Study.
Kurata A; Furuie H; Ishizuka T; Nakatsu T; Shimizu T; Kato M; Nishikawa Y; Ishizuka H
Adv Ther; 2019 Jul; 36(7):1618-1627. PubMed ID: 31119692
[TBL] [Abstract][Full Text] [Related]
32. Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone.
Rakugi H; Yamakawa S; Sugimoto K
Hypertens Res; 2021 Apr; 44(4):371-385. PubMed ID: 33214722
[TBL] [Abstract][Full Text] [Related]
33. Rationale and design of a multicenter randomized study comparing the efficacy and safety of esaxerenone versus trichlormethiazide in patients with uncontrolled essential hypertension: EXCITE-HT study.
Kario K; Ohishi M; Katsuya T; Taguchi T; Tanabe A; Sugimoto K; Shimosawa T
J Clin Hypertens (Greenwich); 2023 Sep; 25(9):861-867. PubMed ID: 37551054
[TBL] [Abstract][Full Text] [Related]
34. Randomized, Double-Blind, Single-Dose, Placebo-Controlled Crossover Study to Evaluate the Effects of Esaxerenone on QTc Interval in Healthy Subjects.
Mendell J; Kobayashi F; Shimizu T
Clin Pharmacol Drug Dev; 2020 Aug; 9(6):709-718. PubMed ID: 32255542
[TBL] [Abstract][Full Text] [Related]
35. CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats.
Arai K; Tsuruoka H; Homma T
Eur J Pharmacol; 2015 Dec; 769():266-73. PubMed ID: 26607463
[TBL] [Abstract][Full Text] [Related]
36. Esaxerenone: First Global Approval.
Duggan S
Drugs; 2019 Mar; 79(4):477-481. PubMed ID: 30806972
[TBL] [Abstract][Full Text] [Related]
37. Reduction in the magnitude of serum potassium elevation in combination therapy with esaxerenone (CS-3150) and sodium-glucose cotransporter 2 inhibitor in patients with diabetic kidney disease: Subanalysis of two phase III studies.
Shikata K; Ito S; Kashihara N; Nangaku M; Wada T; Okuda Y; Sawanobori T; Sugimoto K
J Diabetes Investig; 2022 Jul; 13(7):1190-1202. PubMed ID: 35199478
[TBL] [Abstract][Full Text] [Related]
38. Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice.
Bhuiyan AS; Rafiq K; Kobara H; Masaki T; Nakano D; Nishiyama A
Hypertens Res; 2019 Jun; 42(6):892-902. PubMed ID: 30664703
[TBL] [Abstract][Full Text] [Related]
39. Effects of itraconazole and rifampicin on the single-dose pharmacokinetics of the nonsteroidal mineralocorticoid receptor blocker esaxerenone in healthy Japanese subjects.
Kirigaya Y; Shiramoto M; Ishizuka T; Uchimaru H; Irie S; Kato M; Shimizu T; Nakatsu T; Nishikawa Y; Ishizuka H
Br J Clin Pharmacol; 2020 Oct; 86(10):2070-2079. PubMed ID: 32250463
[TBL] [Abstract][Full Text] [Related]
40. Rationale and Design of the Efficacy and Safety of Esaxerenone in Hypertensive Patients With Left Ventricular Hypertrophy (ESES-LVH) Study - Protocol for a Multicenter, Open-Label, Exploratory Interventional Study.
Sueta D; Yamamoto E; Usuku H; Suzuki S; Nakamura T; Matsui K; Akasaka T; Shiosakai K; Sugimoto K; Tsujita K;
Circ Rep; 2022 Feb; 4(2):99-104. PubMed ID: 35178486
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
